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Multiple system atrophy is a rare and fatal neurodegenerative disorder characterized by progressive autonomic failure,
ataxia and parkinsonism in any combination. The clinical manifestations reflect central autonomic and striatonigral
degeneration as well as olivopontocerebellar atrophy. Glial cytoplasmic inclusions, composed of α-synuclein and other
proteins are considered the cellular hallmark lesion. The cerebellar variant of MSA (MSA-C) denotes a distinctive motor
subtype characterized by progressive adult onset sporadic gait ataxia, scanning dysarthria, limb ataxia and cerebellar
oculomotor dysfunction. In addition, there is autonomic failure and variable degrees of parkinsonism. A range of
other disorders may present with MSA-C like features and therefore the differential diagnosis of MSA-C is not always
straightforward. Here we review key aspects of MSA-C including pathology, pathogenesis, diagnosis, clinical features
and treatment, paying special attention to differential diagnosis in late onset sporadic cerebellar ataxias.
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Multiple system atrophy (MSA) is a rare, sporadic,
progressive, neurodegenerative disorder combining features
of parkinsonism, autonomic dysfunction and cerebellar
and pyramidal signs. MSA can be further classified in
parkinsonian-type MSA (MSA-P) and cerebellar-type
MSA (MSA-C) according to the predominant motor symp-
toms at evaluation.
MSA has a prevalence of 1.9-4.9 cases per 100000 [1,2]
and an incidence of 0.6/100000, raising up to 3/100000 in
people older than 50 years [3].
MSA-P is the more common variant in Europe and in
USA, accounting for about 65% of all cases [4-6]. In the
Japanese population MSA-C is present in 83.8% of MSA
patients at first examination and in 48.6% of patients at
last follow-up [7]. This difference could be caused by,
not yet fully understood, genetic predisposition and
environmental influences in the pathogenesis of the
disease. Median survival ranges from 6 years to about
9 years [6,8,9].
Here, we aim to provide an update on the pathology,
pathogenesis, diagnosis, clinical presentation and latest* Correspondence: gregor.wenning@i-med.ac.at
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unless otherwise stated.therapeutic development in MSA-C. We searched the
following terms on PubMed: “multiple system atrophy”,
“idiopathic late onset cerebellar ataxia”, “sporadic adult
onset ataxia”. In addition, reference lists in review
papers were systematically checked for relevant references.
Only papers in English were reviewed.Review
Pathology
Twenty years ago Papp and coworkers identified, for
the first time, the argyrophilic filamentous aggregates
localized in the cytoplasm of oligodendrocytes that
were common to all MSA variants. These inclusion
bodies were subsequently termed glial cytoplasmic
inclusions (GCIs) or Papp-Lantos bodies [10]. GCIs
are typically associated with gliosis and neuronal loss
in the basal ganglia, cerebellum, pons, inferior olivary
nucleus, and spinal cord. Frequently a striatonigral
(SND) or olivopontocerebellar (OPCA) pattern of
atrophy can be defined. Patients can present either a
balanced damage in both regions or a predominant
involvement of one system over the other. In both
cases, the pathological alteration determines the clinical
phenotype, i.e. clinically diagnosed MSA-C often
reflects underlying OPCA [11-14]. In MSA pathological
alterations are not limited to OPCA and SND but manyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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several autonomic nuclei in the brainstem and spinal cord
is traditionally believed to account for autonomic failure
in MSA [15-17]. However, a growing body of evidence
suggests that post-ganglionic denervation also occurs in
MSA patients, and may be involved in the pathogenesis of
dysautonomia [18-21]. Accordingly, the sudomotor nerve
density in the sweat glands has been found to be reduced
in patients with MSA as compared to healthy controls.
Interestingly, peripheral nerve degeneration has been
found in the early course of the disease, and may,
therefore, be independent of degeneration of autonomic
CNS nuclei [21].
In the late 1990’s, α-synuclein was identified as the
main component of GCIs [22-25]. Widespread GCIs
cannot be found in other diseases and are always
present in patients with MSA, regardless of the clinical
phenotype. Their assessment is considered as the only
reliable criteria for the diagnosis of definitive MSA
[26,27]. Additionally, neuronal cytoplasmic inclusions
(NCIs) and neuronal nuclear inclusions (NNIs) can be
found in MSA as well, however, they are only of limited
diagnostic value [28].
Of note, however, α-synuclein is not the only component
of GCIs. Ubiquitin, tau, p25α, members of the heat
shock protein family, dopamine and c-AMP-regulated
phosphoprotein-32 (DARPP-32), and many other proteins
have been detected in different proportion in GCIs [17].
Of interest, p25α, a normal constituent of myelin sheets in
healthy neurons, seems to have a facilitatory effect on
GCIs formation, and its dislocation from the axons to the
soma of oligodendrocytes [29] might therefore have a
causative role in α-synuclein aggregation [30].
Pathogenesis
Aberrant protein aggregation and dislocation can enhance
neuronal demise [31,32] by disrupting the cytoskeleton
[33]. While NNIs and NCIs directly damage neurons,
GCIs primarily promote oligodendrocytes death [34-36],
thereby causing secondary neurodegeneration. This
assumption is also supported by evidence that GCI
density correlates with disease duration and neuronal
loss [13].
The most accredited theory linking oligodendrocyte
damage with neuronal death focuses on disruption of
the crosstalk between these cells. Oligodendroglial
dysfunction results into an abnormal synthesis and release
of trophic factors and other signal molecules, thereby
triggering neuronal apoptosis [13,37].
Dysfunction of the mitochondrial respiratory chain may
also contribute to the pathophysiology of MSA, as suggested
by the evidence that variants in the COQ2 gene that reduce
the function of parahydroxybenxzoate-polyprenyltransferase
(an enzyme necessary for the biosynthesis of coenzyme Q10)are associated with an increased risk of developing MSA
[38]. Mitochondrial dysfunction leads to an excessive
production of reactive oxygen species (ROS) [39,40],
which have been implicated in the pathogenesis of
MSA-associated neuronal damage [41,42]. ROS species
are also generated by activated microglia, together
with other damaging factors, such as nitrogen species and
cytokines [43-45] (Figure 1) [17]. Microglial activation can
be partially explained by an aberrant expression of
Toll-like receptors (TLRs) in brain regions involved in
OPCA and SND [46]. An imbalance of TLR signaling
could enhance MSA-related brain injury by promoting
pro-inflammatory signals [47,48].
In spite of the recent advances in the understanding
of the pathogenesis of MSA, many questions remain
unanswered. The influence of environmental and genetic
factors remain unresolved in the western hemisphere.
Although early reports suggested an association between
MSA and agricultural work, the role of toxic substances
could not be unequivocally proven [33]. Genetic inheritance
is uncommon and there are few reports of familiar MSA in
the literature [49-51]; however, the genetic background is
important and single nucleotide polymorphisms (SNPs)
of the genes encoding α-synuclein [52-54], the prion
protein [55], and loss of function mutations of the
phenylbenzoate-polyprenyltransferase were shown to
be associated with an increased risk of MSA [38].
The origin of the α-synuclein found in GCIs is still
unknown. Miller and coworkers failed to detect the
expression of the gene coding for α-synuclein (the
SNCA gene) in oligodendrocytes using double-labeling in
situ hybridization technique [56]. Recently, however,
α-synuclein mRNA could be measured in oligodendrocytes
by laser-capture microdissection technique. mRNA levels
in oligodendrocytes did not differ between MSA patients
and healthy controls, although there was a trend to an
increase in MSA patients [57]. Proteosomal and autophagic
degradation of α-synuclein has also been found to be
impaired in affected oligodendrocytes [17,56,58].
An increased uptake of α-synuclein from the extracellular
environment, particularly from the cerebrospinal fluid
(CSF) [59], may also contribute to GCI formation and
propagation [60,61]. Reyes et al. (2014) [61] have
shown that oligodendrocytes grafted in the striatum of rats
overexpressing human α-synuclein, take-up the protein
from surrounding axon terminals. This evidence suggests a
prion-like propagation of α-synuclein in MSA, similarly to
what hypothesized for Parkinson’s disease [62,63].
Clinical features
MSA-C patients develop the first motor or autonomic
symptoms at the mean age of 56 years [64,65]. Postmortem
confirmed MSA-C has never been reported in patients
younger than 30 years. If symptoms appear for the first
Figure 1 Possible pathological a-Syn-spreading and accumulation mechanism leading to neurodegeneration. (A) Healthy neuron,
oligodendrocyte, microglia and astrocyte, p25a mainly located in the myelinating oligodendroglial processes, monomeric a-Syn present in
presynaptic nerve terminals. (B) Relocalisation of p25a from the processes to the soma, inclusion formation and swelling of the oligodendroglial
soma. (C) Oligomeric a-Syn accumulation in the oligodendroglial cytoplasm, the exact source of a-Syn remains to be investigated. Possible
hypotheses include exocytosed a-Syn from neurons and uptake into oligodendrocytes by cell-to-cell propagation or upregulation of a- Syn
expression in oligodendrocytes themselves. In addition, axonal a-Syn may be taken up by the dysfunctional oligodendroglial myelin compartment.
(D) a-Syn aggregates form insoluble half-moon shaped GCIs characteristic for the disease. (E) Disruption of trophic support (e.g. GDNF), mitochondrial
failure, increased production of reactive oxygen species (ROS) and proteasomal dysfunction occur. (F) Oligodendrocytes suffer from severe distress
and will eventually degrade. (G) Activation of micro/astroglial cells by cytokines released from the damaged oligodendrocytes, proposed secondary
neuronal loss potentially due to lack of trophic support, ROS production, proteasomal failure and pro-inflammatory environment. Reproduced with
the courtesy of Elsevier.
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should be questioned [27]. Motor symptoms in MSA-C
are often preceded by autonomic and other non-motor
features [15,64]. Erectile dysfunction and urinary problems,
such as incontinence and urinary retention, are frequentlythe first manifestation of autonomic failure in MSA-C
[15,64,66,67]. Postural faintness tends to occur later
[15,64,66,68]. Other symptoms of autonomic failure in
MSA-C include reduced sweating and constipation.
Recently, Iodice and colleagues (2012) [69] reported that
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is ataxic gait, followed by dysarthria, limb ataxia and
gazed-evoked nystagmus. Although nystagmus is uncom-
mon, other oculomotor abnormalities, such as jerky
pursuit, square wave jerks, and dysmetric saccades are
frequently observed in the early course of the disease
[27]. Hyperreflexia and positive Babinski sign are classical
manifestations of pyramidal tract degeneration and are
frequently assessed in MSA-C patients.
Parkinsonism occurs about 5 years after the onset of
MSA-C [70] and is usually characterized by an akinetic-
rigid syndrome. Parkinsonian symptoms in MSA-C patients
may respond to levodopa (L-DOPA) in up to 51% of cases,
however, the effect is often transient and some patients also
develop L-DOPA-induced dyskinesias [65].
Craniocervical dystonia is a common cause of postural
aberrations such as camptocormia and Pisa syndrome.
Dystonic involvement of face, hands and feet is also
possible. Laryngeal abductor palsy resulting in stridor, can
also be present. It commonly appears late in the disease
course and is a possible cause of sudden death [71].
Ataxia, parkinsonism and postural impairment all
contribute to gait instability, occurring early after the
disease onset [64,72].
Microcirculatory abnormalities are common in MSA-C
patients and are responsible for the so called “cold hand
sign” [73-75].
Tison and colleagues [76] reported that about 30%
of patients with MSA-C experience pain. The most
common form is musculoskeletal pain, followed by
sensory and dystonic pain.
Almost all patients with MSA develop REM sleep
behavior disorder (RBD), a condition that is characterized
by violent movements and nightmares during REM sleep
[77]. In a small series of 13 MSA-C patients, RBD was
found to precede waking motor symptoms in 3 patients
and was present at diagnosis in about 50% of cases [78].
Curiously, RBDs commonly improve along with disease
progression [75]. Excessive daytime sleepiness has been
reported in about 25% of MSA-C patients, and might stem
from low quality of sleep and/or dysfunction in neuronal
pathways of arousal [79,80].
Many authors described cognitive impairment, involving
executive functions and verbal learning in MSA-C [81-86].
These deficits are probably due to frontal atrophy [82,84]
and white matter networks disruption [81,87].
Finally, psychiatric syndromes such as depression [86],
anxiety [85] and pathological laughing and crying [88],
affect MSA-C patients more frequently than the general
population.
Diagnosis
According to current consensus diagnostic criteria [27],
three different categories of increasing diagnostic certaintywere defined. A definite diagnosis of MSA requires
post-mortem examination. Probable MSA-C is defined
by the presence of cerebellar ataxia and either limb
ataxia, cerebellar dysarthria or cerebellar oculomotor
dysfunction, together with autonomic dysfunction in the
form of urinary incontinence and erectile dysfunction or
severe orthostatic hypotension defined as a drop in systolic
or diastolic blood pressure of 30 mmHg and 15 mmHg
within 3 minutes after standing, respectively.
If only a mild autonomic dysfunction is found, possible
MSA-C can be diagnosed taking into account pyramidal
signs, parkinsonism, and imaging findings. T2-weighted
MRI can reveal the so called “hot cross bun sign”, a
cruciform hyperintensity in the ventral part of pons. This
is one of the most distinctive although not pathognomonic
imaging findings in MSA-C and has been reported in up
to 81.4% of patients [64]. It is due to demyelation and
fibrosis of transverse fibers in pons and it can be assessed
also in other pathologies involving the pons, such as
different types of SCAs, particularly SCA 2 [89]. Middle
cerebellar peduncle hypointensity, lateral putaminal rim
hyperintensity and putaminal hypointensity, are also
considered in the diagnosis of possible MSA-C.
Diffusion weighted imaging (DWI) and diffusion
tensor imaging (DTI) are MRI techniques that are
considered still investigational in the latest MSA
guidelines [27]. They can detect early alterations in
the infratentorial region of MSA patients [90,91] and
show a higher sensitivity compared to T2-weighted
MRI for the “hot cross bun sign” [92]. Because of its
high sensitivity, DTI might be helpful for the differential
diagnosis in patients with cerebellar symptoms even in the
earlier stages of MSA-C, (see below). DWI and DTI have
also been proposed as possible markers for the progression
of the disease [93].
Striatal dopaminergic denervation or glucose hypometa-
bolism assessed with SPECT or PET, respectively, in the
presence of cerebellar symptoms suggests the diagnosis of
MSA-C rather than other forms of late onset ataxia
(Table 1).
Warning symptoms, also called “red flags”, may facilitate
the diagnosis of MSA (Table 2) [94]. Disease progression
can be quantified using the Unified MSA Rating
Scale (UMSARS) [95]. It involves assessment of the
activities of daily living (ADL) (UMSARS I), the motor
function (UMSARS II), a simple standing test to determine
the presence and magnitude of OH (UMSARS III)
and a global disability scale (UMSARS IV).
Differential diagnosis
MSA-like cerebellar symptoms, are shared by many other
primary and secondary cerebellar disorders. Secondary
ataxia can be caused by toxins, infections, tumors, vitamin
deficiency and several other pathologies. Primary diseases
Table 1 Diagnosis of MSA-C, modified from Gilman et al., 2008 [27]
Probable MSA-C: Possible MSA-C:
A sporadic progressive, adult (>30y)- onset disease characterized by: A sporadic progressive, adult (>30y)- onset disease characterized by:
• Autonomic failure involving urinary incontinence (inability to control
the release of the urine from the bladder, with erectile dysfunction in males)
or an orthostatic decrease of blood pressure with 3 min of standing by at
least 30 mmHg systolic or 15 mmHg diastolic
• Cerebellar syndrome
• At least one feature suggesting autonomic dysfunction (otherwise
unexplained urinary urgency, frequency, incomplete bladder emptying,
erectile dysfunction, in males, or significant orthostatic blood pressure
decline that does not meet the level required in probable MSA-C)
• Cerebellar syndrome • At least one of the following feature:
○ Babinski sing with hyperreflexia
○ Stridor
○ Parkinsonism (bradykinesia and rigidity)
○ Atrophy on MRI of putamen, middle cerebellar peduncle, or pons
○ Hypomethabolism on FDG-PET in putamen
○ Presynaptic nigrostriatal dopaminergic denervation on PET or SPECT
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(SCAs) and Fragile-X related tremor and ataxia syndrome
(FXTAS)), or remain idiopathic.
Alcohol is a common cause of ataxia, with the percentage
of alcoholics developing ataxia ranging from 11% to 27%Table 2 Red flags for MSA, reproduced with the courtesy of W
Red flag



















Emotional incontinence – crying
Emotional incontinence – laughing
Past history of documented hypertension[96,97]. The possible relation between alcohol intake
and cerebellar symptoms should be carefully assessed
for a correct diagnosis. An improvement of symptoms
after alcohol withdrawal is strongly indicative for alcoholic
ataxia [98,99].iley and Sons [85]
Definition
within 3 years of disease onset
“wheelchair sign”: dependent < 10 years from disease onset
based on clinical judgment
prolonged episodes of forward trunk flexion
prolonged episodes of lateral trunk flexion
severe neck flexion, minor flexion elsewhere
excluding Dupuytren’s or contracture due to other known cause
irregular postural or action tremor of the hands and/or fingers
with definite myoclonus
based on clinical judgment
based on clinical judgment
involuntary deep inspiratory sighs/gasps
based on clinical judgment
based on clinical judgment
based on clinical judgment
intermittent loss of muscle atonia and appearance of elaborate
motor activity (striking out with arms in sleep often with
talking/shouting) associated with dream mentation
prolonged arrests of breathing
increase from premorbid level, or newly arising
new development of coldness and color change – purple/blue – of
extremities, with blanching on pressure and poor circulatory return
new emergence of painful “white fingers”
Inappropriate crying without sadness
Inappropriate laughing without mirth
based on clinical judgment
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It is, therefore, important to evaluate all medications taken
by the patients, keeping in mind their possible adverse
effects.
An important cause of late onset ataxia is a paraneoplastic
syndrome. Small cell lung cancer, ovarian cancer, breast
cancer, and Hodgkin's lymphoma are most usually
associated with cerebellar injury [98]. This damage is
commonly related with the production of circulating
antineural antibodies directed against antigens expressed
by neoplastic cells [104,105]. Peripheral blood testing,
combined with the assessment of rapid progressive
ataxia and systemic symptoms such as fever, malaise
and anorexia in the absence of cerebellar abnormalities at
MRI at the onset of motor symptoms, usually leads to the
diagnosis of paraneoplastic cerebellar ataxia within
6 months [104]. Vitamin deficiency, superficial siderosis
and infections can also cause ataxia (reviewed by
Klockgether, 2010) [98].
Finally, ataxia can also be associated with autoimmune
disorders. Anti-glutamate decarboxylase (GAD) antibodies
positive ataxia is more frequent in diabetic patients
[106] and in patients with polyglandular autoimmune
disorder [107]. Gluten ataxia is a sporadic form of
ataxia developing after chronic ingestion of gluten,
with or without association with coeliac disease. Gluten
ataxia is diagnosed if antigliadin antibodies are found in
ataxic patients in the absence of other potential causes
[108,109]. Anti-transglutamminase (TG) autoantibodies
can also be found in patients with gluten ataxia. In
particular, antibodies directed against TG 6, the most abun-
dant TG isoform in the CNS, are specifically associated
with gluten ataxia [110].
The collection of an accurate family history is important,
but not always sufficient, to rule out genetic forms of
ataxia. Late onset autosomal dominant SCAs, such as
SCA6 [111,112], may be difficult to diagnose if the affected
relatives died before developing the illness. In a study,
genetic analysis was performed in patients with negative
family history who developed ataxia when they were at
least 25 years old. SCA6 was the predominant genetic
form, but also mutations associated with SCA2 and SCA3
were found in few patients [113]. It is worth noting that in
Asiatics and Africans SCA2 and SCA3 mutations cause
L-DOPA-responsive parkinsonism [114,115].
A premutation of the FMR1 gene causes a late onset
form of ataxia called FXTAS. This disease is characterized
by cerebellar ataxia, postural and intentional tremor,
dementia, neuropathy, and several psychiatric manifesta-
tions [116]. A large investigation by Kamm and coworkers
(2005) [117] showed that FMR1 premutation-associated
ataxia is distinct from MSA-C. Nevertheless, the possible
diagnosis of FXTAS has to be considered especially in the
presence of slow disease progression, neuropathy anddementia. These clinical features are common among
patients with FXTAS, and their assessment may help
to differentiate the two disorders.
Most of the above conditions can be diagnosed with
an accurate history. It is more difficult to differentiate
MSA-C with sporadic adult onset ataxia (SAOA). SAOA,
also known as idiopathic late onset cerebellar ataxia
(ILOCA), is a rare form of ataxia, with a prevalence of
about 8.4 per 100000 [118]. The age at onset for both
MSA-C and SAOA is around 50 years [118]. However, the
mean survival time is much longer in SAOA than in
MSA-C. SAOA is not only associated with a better
prognosis but also with a delayed deterioration in ADL.
Patients with MSA require a wheelchair within 5 years of
onset [64]; in contrast, about half of patients with SAOA
can still walk unaided after 12 years [113,119].
A reliable differential diagnosis between SAOA and
MSA-C can usually be performed years after the onset.
Within 5 years from the diagnosis, about ¼ of patients
with idiopathic late onset cerebellar ataxia are diagnosed
as affected by MSA-C [113,120,121]. This can be easily
explained considering that the presence of autonomic
and motor signs is mandatory for the diagnosis of MSA-C
[27] and that autonomic dysfunction becomes manifest
only 2–2.5 years after the first cerebellar signs
[64,70]. Initial clinical presentation do not help much
in the differential diagnosis. Although nystagmus, gaze
paralysis, decreased or absent ankle reflex are more
common in SOAO [121,122], many motor and non-motor
symptoms [123], RBD [75,122] and erectile dysfunction
[68,122], are shared by MSA-C and SAOA.
The differential diagnosis between SAOA and MSA-C
has been the subject of several studies. However, the
large majority of these studies compared fully developed
MSA and SAOA, whereas the differential diagnosis is
particularly difficult in the early phase of the disease.
T2-weighted MRI is used for the diagnosis of MSA [27]
and has good specificity in differentiating fully developed
MSA-C from SAOA [124]. Other MRI based techniques
were used for the differential diagnosis between MSA-C
and other ataxias, with interesting results. Proton MR
spectroscopy imaging distinguished MSA-C from SCA2
on the basis of different levels of lactate in cerebellum
[125]. DTI yielded a different fractional anisotropy in
MSA-C and many other types of ataxia, but not SAOA
[126]. A more valuable diagnostic tool is the measurement
of cerebral blood flow in the pons by Fine-STR, which is
lower in MSA-C than in SAOA [127].
In MSA-C there is loss of motor units innervating the
external anal and urethral sphincter muscles reflecting
degeneration of Onuf ’s nucleus. These changes together
with detrusor hyperreflexia account for early neurogenic
bladder incontinence in MSA-C and they may help differ-
entiate MSA-C from other sporadic late onset cerebellar
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[128]. Sphincter denervation can be evaluated by means of
anal sphincter electromyography (EMG) and urethral
sphincter EMG [128-132]. The former is better tolerated
by patients [129]. However, anal sphincter EMG is not
highly sensitive in the early course of the disease, and it
was positive only in 52% of patients with disease duration
shorter than 1 year [130].
Measurements of proteins and monoamine metabolites
in the cerebrospinal fluid (CSF) are particularly valuable
in the diagnosis of chronic neurodegenerative disorders.
Putative CSF biomarkers include neurofilament light
chain (NFL), phosphorylated neurofilament heavy chain,
α-synuclein, β-amyloid, tau, the noradrenaline metabolite,
3-methoxy-4-hydroxyphenylethylenglycol (MHPG), and
the dopamine metabolites, dihydroxyphenylacetic and
homovanillic acids [58,133-136]. Abdo et al. (2006) [137]
have found that a combined measurement of NFL, MHPG
and tau has 100% specificity in differentiating between
MSA and SAOA. Interestingly, the CSF obtained from
MSA patients promotes aggregation of α-synuclein to
a greater extent than the CSF obtained from SCAs
patients [138].
For the diagnosis of MSA-C, EMG and CSF analysis are
generally not recommended [27], because they are not
helpful in full blown cases and have not been jet validated
in early cases.
Treatment
Currently, the only treatments available for MSA-C are
symptomatic. There are no approved drugs that can
influence the disease course. The management of all
possible manifestations of MSA is described in detail else-
where [139-141]. Here, we will offer a brief description of
the main therapeutic options that are currently available
and will focus on new drugs under development.
Symptomatic treatment
Parkinsonism associated with MSA-C is treated with
L-DOPA. Only half of patients with MSA-C respond
to L-DOPA and dyskinesias, usually facial, are a common
side effect [65]. When starting L-DOPA, a responsiveness
test should be made with escalating doses in the first
3 months (up to a daily dose of 1000 mg if needed
and tolerated) [142].
Currently, there is no treatment for cerebellar ataxia.
The hypothesis of a possible effect of anticholinergic
drugs is supported by the evidence that nicotine, which
stimulates nicotinic cholinergic receptors in the CNS, can
cause a reversible worsening of ataxic symptoms [10,143].
Urinary problems could be managed with drugs, at
least at the beginning of the disease. The antimuscarinic
drug, oxybutinine, reduces detrusor hyperreflexia and
sphincter-detrusor dyssynergia, with positive effects onurgency and frequency [128,144]. Urinary retention is
treated with α1-adrenergic antagonists, such as prazosin
and moxysylate. All these drugs have important adverse
effects that could limit their use. If postvoid residual
volume exceeds 150 ml, although potentially difficult for
ataxic patients, clean intermittent self-catheterization is
indicated [144]. Many patients will eventually require a
suprapubic catheter.
Orthostatic hypotension can be managed with non-
pharmacological strategies. Adequate hydration of
the patient has to be guaranteed [145]. Moreover, the
patients should avoid large meals and increase sodium
intake. Sitting or lying if feeling dizzy is recommended; if
this is not possible, crossing legs, contracting thighs, and
bending over can be helpful [146]. Abdominal and leg
elastic garments are also effective in reducing orthostatic
hypotension. Head-up tilt while sleeping reduces cerebral
hypertension and increases circulatory volume within
1 week [140].
If these non-pharmacological measures fail, medical
treatment is needed. Fludrocortisone is a potent agonist of
mineralcorticoid receptors and increases blood pressure by
enhancing sodium reuptake in the kidney. Alternatively,
patients may be treated with the α1 adrenergic agonist,
midodrine, or with the recently FDA approved adrenergic
prodrug, droxidopa [147]. Finally, the vasopressin analogue,
desmopressin, reduces nocturnal polyuria and morning
hypotension [148].
Patients with postprandial hypotension may gain
benefit by treatment with somatostatin analogues [141],
which likely act by inhibiting the release of vasoactive
gastrointestinal peptides [149].
Constipation is managed with high-fiber diet and, if
necessary, macrogol-water solution.
Physiotherapy, speech therapy and occupational therapy
may help patients coping with their disease [141].
New treatments
In the last years, many drugs have been tested as potential
disease modifiers in MSA in general and MSA-C in
particular. A growing body of evidence suggested efficacy
in transgenic MSA mouse models [17]. However, growth
hormone (GH) [150], the antiglutamatergic drug, riluzole
[151], minocycline [152], rifampicin [153], and lithium
[154] all failed to slow or halt disease progression in
humans. A common feature of clinical trials with all
these drugs, was to include patients in advanced
stages, with fewer chances of gaining benefit by putative
neuroprotective agents.
A Korean publication [155] reported beneficial effects
of autologous bone marrow derived mesenchymal stem
cells (MSC) in MSA patients, however these results have
not been replicated so far and therefore remain experi-
mentally until further confirmation studies are completed.
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intravenous infusion of immunoglobulins, which are
known to exert anti-inflammatory activity [156].
Seven MSA patients have been treated for 6 months
and showed an improvement in UMSARS I and
UMSARS II subscales, whereas UMSARS III and
UMSARS IV remained unchanged [157]. This study
was carried out on a small number of patients, without a
control group. However, bearing in mind that a large
deterioration in UMSARS is usually seen in one year
[158], results are promising. In addition, α-synuclein
lowering strategies have shown efficacy in preclinical
synucleinopathy models, thus raising the possibility that
these strategies may ultimately arrest disease progression
in MSA [159].
Conclusions
Further advances in the diagnosis and treatment of MSA
will go hand in hand. Novel neuroprotective strategies
will be tested with the aid of novel diagnostic tools that
allows an earlier start of the treatment.
Many ancillary exams with possible diagnostic value,
such as MRI, anal sphincter EMG, CSF analysis and GH
testing have been evaluated in MSA compared to other
diseases. In our opinion, it becomes necessary to apply
these diagnostic tools in patients with idiopathic cerebellar
ataxia [113,120,121]. Hopefully, this new techniques will
facilitate a differential diagnosis between MSA-C and
SAOA at earlier time points. Clearly much is changed
and many steps forward have been taken since Quinn
portrayed MSA as a beast, in 1989 [160].
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